Investigational drug · Phase 2
KAN-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease, Coeliac Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "KAN-101"
First trial start
2023
Dec 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KAN-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Celiac Disease
- Coeliac Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "KAN-101" as an intervention, largest first.
- A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)Pivotal-lookingTerminated
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SAIndustry
NCT05574010 · 128 participants · Start Nov 15, 2022 · Primary completion Nov 29, 2024
Drug: Cohort 1 in Part A; Cohort 2 in Part A and 3 more · For: Celiac Disease
Sites: Birmingham, Alabama; Anaheim, California; St. Petersburg, Florida · 36 sites in all
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SAIndustry
NCT06001177 · 55 participants · Start Dec 13, 2023 · Primary completion Jan 3, 2025
Drug: KAN-101; Placebo · For: Celiac Disease; Coeliac Disease
Sites: Colorado Springs, Colorado; Hialeah Gardens, Florida; Miami, Florida · 28 sites in all
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SAIndustry
NCT04248855 · 41 participants · Start Jan 21, 2020 · Primary completion Oct 8, 2021
Drug: KAN-101; Placebo · For: Celiac Disease
Sites: Anaheim, California; Walnut Creek, California; Aventura, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
Girbal-González M, Pérez-Cano FJ · Nutrients 2025
- Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial.
Murray JA, Wassaf D, Dunn K, et al. · Lancet Gastroenterol Hepatol 2023
Also in development for Celiac Disease
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- Larazotide AcetatePhase 31 trial
Interlude Biopharma Co. · Celiac Disease, Celiac Disease in Adolescents
- DONQ52Phase 21 trial
Chugai Pharmaceutical · Celiac Disease
- FB102Phase 21 trial
Forte Biosciences, Inc. · Celiac Disease
- TAK-101Phase 21 trial
Takeda · Celiac Disease
- ZED1227Phase 21 trial
Dr. Falk Pharma GmbH · Celiac Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.